Global Registrational Ph 3 Study of Lisaftoclax in 1L CLL/SLL Patients Approved by the China CDE October 25, 2023
Enrollment ex-China in Ph 3 REGAL Trial for Galinpepimut-S in AML Expected to be Completed in Nov 2023 October 18, 2023
First Subjects dosed in Ph 2 Portion of Trial Evaluating Annamycin + Cytarabine (Ara-C) for the Treatment of AML October 11, 2023
Ph 3 ENHANCE-2 study of magrolimab in patients with AML with TP53 mutations discontinued October 3, 2023
European Commission Approves Enrylaze for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma October 3, 2023
European Commission approved INAQOVI® (oral decitabine and cedazuridine) for 1L AML patients September 26, 2023
Quizartinib Recommended for Approval in EU by CHMP for Patients with Newly Diagnosed FLT3-ITD Positive AML September 19, 2023
First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy Announced August 23, 2023
VANFLYTA® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML August 16, 2023
EMA Approves Clinical Trial Application (CTA) for AVC-201 for the Treatment of R/R AML and other CD123 Hematological Malignancies August 2, 2023
CHMP Positive Opinion for JZP458 for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma August 2, 2023
VANFLYTA First FLT3 Inhibitor Approved in the U.S. Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML July 27, 2023
Registrational Pivotal Phase III Study of Olverembatinib for the First-Line Treatment of Patients with Ph+ ALL Approved by the CDE in China July 19, 2023
Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States July 12, 2023
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID July 12, 2023
NEJM Publishes BRUIN Ph 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with CLL/SLL July 12, 2023
